Betahistine STADA 24 mg Tablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

betahistine stada 24 mg tablett

stada arzneimittel ag - betahistindihydroklorid - tablett - 24 mg - mannitol hjälpämne; betahistindihydroklorid 24 mg aktiv substans

Betahistine STADA 8 mg Tablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

betahistine stada 8 mg tablett

stada arzneimittel ag - betahistindihydroklorid - tablett - 8 mg - betahistindihydroklorid 8 mg aktiv substans; mannitol hjälpämne

Betahistine STADA 16 mg Tablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

betahistine stada 16 mg tablett

stada arzneimittel ag - betahistindihydroklorid - tablett - 16 mg - mannitol hjälpämne; betahistindihydroklorid 16 mg aktiv substans

Betahistine Sandoz 8 mg Tablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

betahistine sandoz 8 mg tablett

sandoz a/s - betahistindihydroklorid - tablett - 8 mg - betahistindihydroklorid 8 mg aktiv substans; laktosmonohydrat hjälpämne

Betahistine Sandoz 16 mg Tablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

betahistine sandoz 16 mg tablett

sandoz a/s - betahistindihydroklorid - tablett - 16 mg - betahistindihydroklorid 16 mg aktiv substans; laktosmonohydrat hjälpämne

Orladeyo Europeiska unionen - svenska - EMA (European Medicines Agency)

orladeyo

biocryst ireland limited - berotralstat dihydrochloride - angioödemar, ärftlig - other hematological agents - orladeyo is indicated for routine prevention of recurrent attacks of hereditary angioedema (hae) in adult and adolescent patients aged 12 years and older.

Ceplene Europeiska unionen - svenska - EMA (European Medicines Agency)

ceplene

laboratoires delbert - histamin dihydrochloride - leukemi, myeloid, akut - immunstimulatorer, - ceplene maintenance therapy is indicated for adult patients with acute myeloid leukaemia in first remission concomitantly treated with interleukin-2 (il-2). effekten av ceplene har inte visats fullständigt hos patienter som är äldre än 60 år.

Cufence Europeiska unionen - svenska - EMA (European Medicines Agency)

cufence

univar solutions bv - trientin dihydrochloride - hepatolentikulär degeneration - andra matsmältningsorgan och ämnesomsättning produkter, - cufence är indicerat för behandling av wilsons sjukdom hos patienter intoleranta mot d-penicillamin behandling, vuxna och barn som är 5 år eller äldre.

Inrebic Europeiska unionen - svenska - EMA (European Medicines Agency)

inrebic

bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - antineoplastiska medel - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.

Sapropterin Dipharma Europeiska unionen - svenska - EMA (European Medicines Agency)

sapropterin dipharma

dipharma arzneimittel gmbh - sapropterin dihydrochloride - phenylketonurias - andra matsmältningsorgan och ämnesomsättning produkter, - sapropterin dipharma is indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with phenylketonuria (pku) who have been shown to be responsive to such treatment. sapropterin dipharma is also indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with tetrahydrobiopterin (bh4) deficiency who have been shown to be responsive to such treatment.